KR20170045085A - Composition for improving skin and its use - Google Patents
Composition for improving skin and its use Download PDFInfo
- Publication number
- KR20170045085A KR20170045085A KR1020150180221A KR20150180221A KR20170045085A KR 20170045085 A KR20170045085 A KR 20170045085A KR 1020150180221 A KR1020150180221 A KR 1020150180221A KR 20150180221 A KR20150180221 A KR 20150180221A KR 20170045085 A KR20170045085 A KR 20170045085A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- composition
- vitamin
- pine bark
- bark extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 99
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 102
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 98
- 230000006872 improvement Effects 0.000 claims abstract description 57
- 235000020741 pine bark extract Nutrition 0.000 claims abstract description 54
- 229940106587 pine bark extract Drugs 0.000 claims abstract description 53
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 51
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 51
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 51
- 239000011709 vitamin E Substances 0.000 claims abstract description 51
- 229940046009 vitamin E Drugs 0.000 claims abstract description 51
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims abstract description 50
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims abstract description 50
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims abstract description 50
- 229960002733 gamolenic acid Drugs 0.000 claims abstract description 50
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 48
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 48
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 48
- 206010061218 Inflammation Diseases 0.000 claims abstract description 37
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 35
- 206010000496 acne Diseases 0.000 claims abstract description 35
- 230000036039 immunity Effects 0.000 claims abstract description 34
- 239000011148 porous material Substances 0.000 claims abstract description 30
- 210000002374 sebum Anatomy 0.000 claims abstract description 30
- 230000037394 skin elasticity Effects 0.000 claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 claims abstract description 27
- 230000008591 skin barrier function Effects 0.000 claims abstract description 26
- 238000010606 normalization Methods 0.000 claims abstract description 25
- 239000002537 cosmetic Substances 0.000 claims abstract description 21
- 230000036541 health Effects 0.000 claims abstract description 20
- 230000008602 contraction Effects 0.000 claims abstract description 18
- 230000036548 skin texture Effects 0.000 claims abstract description 17
- 235000013376 functional food Nutrition 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000005764 inhibitory process Effects 0.000 claims abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 19
- 230000003020 moisturizing effect Effects 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000002131 composite material Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 235000010204 pine bark Nutrition 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 44
- 102000016942 Elastin Human genes 0.000 abstract description 17
- 108010014258 Elastin Proteins 0.000 abstract description 17
- 229920002549 elastin Polymers 0.000 abstract description 17
- 229920002674 hyaluronan Polymers 0.000 abstract description 13
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 12
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 12
- 230000015572 biosynthetic process Effects 0.000 abstract description 11
- 238000003786 synthesis reaction Methods 0.000 abstract description 11
- 102000004127 Cytokines Human genes 0.000 abstract description 9
- 108090000695 Cytokines Proteins 0.000 abstract description 9
- 210000002950 fibroblast Anatomy 0.000 abstract description 8
- 230000002757 inflammatory effect Effects 0.000 abstract description 8
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 119
- 230000000052 comparative effect Effects 0.000 description 40
- 235000013305 food Nutrition 0.000 description 21
- 238000009472 formulation Methods 0.000 description 20
- 230000001629 suppression Effects 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 12
- 230000032683 aging Effects 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 11
- 229920002770 condensed tannin Polymers 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 235000018192 pine bark supplement Nutrition 0.000 description 10
- 229940106796 pycnogenol Drugs 0.000 description 10
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 9
- 235000011613 Pinus brutia Nutrition 0.000 description 9
- 241000018646 Pinus brutia Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- -1 proanthocyanidin Chemical class 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000009759 skin aging Effects 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000009931 harmful effect Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 229940085469 ascorbic acid 300 mg Drugs 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 229940079877 pyrogallol Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- HNICUWMFWZBIFP-IRQZEAMPSA-N 13(S)-HODE Chemical compound CCCCC[C@H](O)\C=C\C=C/CCCCCCCC(O)=O HNICUWMFWZBIFP-IRQZEAMPSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 239000012875 nonionic emulsifier Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000020238 sunflower seed Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-M D-tartrate(1-) Chemical compound OC(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-M 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851054 Homo sapiens Elastin Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical compound [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000054289 human ELN Human genes 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GNHOJBNSNUXZQA-UHFFFAOYSA-J potassium aluminium sulfate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GNHOJBNSNUXZQA-UHFFFAOYSA-J 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
본 발명은 피부 탄력 개선, 모공 수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 효과를 나타내는 피부 개선용 조성물에 관한 것이다. The present invention relates to a composition for skin improvement which shows skin elasticity improvement, pore contraction, antibacterial, acne control, sebum control, skin barrier improvement, skin immunity normalization, anti-inflammation, trouble improvement, skin moisturization and skin texture improvement.
노화는 생명의 현상으로, 모든 생명체는 태어나면서부터 노화가 시작된다. 위생과 보건환경 개선으로 인간 수명은 지난 과거보다 상당히 연장되었으며, 고령 인구의 비율은 꾸준히 증가하고 있는 추세이다[비특허문헌 1]. 노화는 신체에 전체적으로 일어나는데, 전반적인 신체기능 저하 및 심혈관 질환, 당뇨와 같은 생활 습관병과 같이 장기들의 생리적 기능이 저하된다[비특허문헌 2].Aging is a phenomenon of life, and all life begins from the birth of aging. Due to the improvement of sanitation and health environment, human life span has been significantly extended, and the proportion of the elderly population is steadily increasing [Non-Patent Document 1]. Aging occurs entirely in the body, which deteriorates physiological functions of organs such as general physical dysfunction and lifestyle diseases such as cardiovascular diseases and diabetes [Non-Patent Document 2].
피부는 몸의 가장 바깥에서 체내의 수분, 전해질, 단백질이 소실되는 것을 막아주면서, 체온 조절, 피부의 감각 기능, 면역 기능 등 여러 가지 역할을 동시에 수행하는 중요 기관이다. Skin is an important organ that performs various roles such as body temperature control, skin sensory function, and immune function while preventing moisture, electrolytes and proteins from disappearing from the outermost part of the body.
피부 역시 다른 기관과 마찬가지로 나이가 들어감에 따라 노화가 진행된다. 피부노화는 내인성 피부노화(intrinsic skin aging)와 광노화(photoaging)로 구성되며, 내인성 피부 노화는 육안적인 형태학적 변화보다는 기능적 변화를 특징으로 한다. 만성 자외선 노출에 의한 광노화는 내인성 노화와 중첩되며, 전신적이거나 피할 수 없는 것은 아니지만, 현저한 구조적, 생리적 변화가 나타난다. 노화된 표피에서는 피부의 주름 발생, 장벽 소실, 면역 이상 등의 고유의 기능 이 상실될 뿐 아니라 신체의 외관에 심미적으로 영향을 준다. 피부의 노화를 막을 수 있는 없지만, 피부의 노화를 예방하고 늦추는데 다양한 시도들이 행하여지고 있다.As with other organs, skin ages with age. Skin aging consists of intrinsic skin aging and photoaging, and endogenous skin aging is characterized by functional changes rather than gross morphological changes. Photoaging due to chronic UV exposure overlaps with endogenous aging and is not systemic or unavoidable, but it has significant structural and physiological changes. In the aged epidermis, not only the inherent functions such as wrinkles of the skin, loss of the barrier, immunity abnormality, etc. are lost, but also affect the appearance of the body aesthetically. There is no way to prevent aging of the skin, but various attempts have been made to prevent and slow the aging of the skin.
한편, 소나무 껍질 추출물은 소나무 속(Pinus)에 속하는 소나무로부터 추출한 것으로써, 다양한 소나무 껍질 추출물 중 특히 프랑스산 해송 추출물인 피크노제놀(Pycnogenol)에 관해서는 다양한 논문들이 발표되어 있다. 피크노제놀의 효과로는 순환계 혈관 관련 개선 효과[비특허문헌 3], 항산화 효과[비특허문헌 4, 5, 6], 피부 흑화 억제 및 염증 억제 효과[비특허문헌 7, 8], 콜라겐 단백질 분해 억제 효과[비특허문헌 9] 등에 대해 발표되어 있다. On the other hand, pine bark extract was extracted from pine belonging to Pinus (pine), and various papers on pycnogenol which is a French sea otopus extract among various pine bark extracts have been published. The effects of pycnogenol include circulating blood vessel-related improvement effects [Non-Patent Document 3], antioxidant effects [Non-Patent Documents 4, 5 and 6], inhibition of skin blackening and inflammation inhibition [Non-Patent Documents 7 and 8] Effect [Non-Patent Document 9] and the like.
또한, 아스콜빈산과 비타민 E는 항산화 효과가 매우 뛰어난 비타민으로 인체에 대한 유해성이 전혀 없는 성분이다. 아스콜빈산과 비타민 E는 함께 과량 복용하였을 경우 최소 홍반 조사량(MED)가 증가한다는 보고가 있어 과량 복용시 염증 억제 효과가 있는 것으로 추정되고 있다[비특허문헌 10, 11].In addition, ascorbic acid and vitamin E are vitamins that are highly antioxidant and have no harmful effects on the human body. Ascorbic acid and vitamin E have been reported to increase the minimum erythemal dose (MED) when administered in combination with an overdose, which is presumed to have an inflammation-suppressing effect upon overdose (Non-Patent Documents 10 and 11).
또한, 감마리놀렌산은 달맞이종자유, 보라지유, 호박씨유, 우엉씨(우방자)유 등에 다량 함유되어 있는 성분이다. 감마리놀렌산은 피부의 표피에서 13-HODE(13-Hydroxyoctadecadienoic acid)로 전환된 후 인지질에 병합되어 피부의 과증식을 억제하고 또한 피부 보습 기능을 가질 수 있다는 논문이 발표되어 있다[비특허문헌 12].In addition, gamma linolenic acid is a component that is contained in large amounts in sunflower seed oil, borage oil, pumpkin seed oil, burdock seed oil, and the like. It has been reported that gamma linolenic acid can be converted into 13-hydroxyoctadecadienoic acid (13-HODE) from the epidermis of the skin, and then incorporated into phospholipids to inhibit skin hyperplasia and also to have skin moisturizing function [Non-Patent Document 12].
기존 선행 특허에서는 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산이 혼합된 복합체의 미백, 주름 개선 및 억제 기능성 효과를 기재하고 있다[특허문헌 1, 2]. 그러나, 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산이 혼합된 복합체가 피부의 탄력 개선, 모공수축, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 항균 피부 보습, 피부결 개선, 피지조절에 효과가 있다는 것은 보고된바 없다.The prior art patents disclose whitening, wrinkle-improving and inhibiting functional effects of pine bark extract, ascorbic acid, vitamin E, and gamma linolenic acid-mixed complex [Patent Literatures 1 and 2]. However, a complex of pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid improves skin elasticity, shrinks pores, improves skin barrier, normalizes skin immunity, anti-inflammation, improves trouble, There has been no reported effect on the regulation.
이러한 배경 하에, 본 발명자들은 피부 노화 억제 효과가 있는 천연물 소재를 개발하고자 노력한 결과, 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산이 혼합된 복합체가 피부의 피부 탄력 개선, 모공수축, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 항균, 피부 보습, 피부결 개선, 피지조절에 효과가 있음을 확인하고 본 발명을 완성하였다.Under these circumstances, the present inventors have made efforts to develop a natural material having an effect of inhibiting skin aging. As a result, it has been found that a complex of pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid improves skin elasticity of skin, The present invention has been completed upon confirming that the present invention is effective in improving skin immunity, improving skin irritation, improving anti-inflammation, improving trouble, antibacterial, skin moisturizing, skin texture and sebum control.
이에, 본 발명자들은 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물이 피부의 섬유아세포의 엘라스틴 합성을 촉진하여 피부 탄력 개선, 모공 수축 효과를 나타내고, 슈퍼옥시드 디스무타아제 유사 활성을 통해 항산화 효과를 나타내며, 염증성 사이토카인의 수준을 정상화하여 피부 면역 정상화, 항염, 트러블 개선 효과를 나타내고, 피부 상재균 증식을 억제하여 여드름 억제, 항균 효과가 있으며, 히알루론산의 합성을 촉진하여 피부 보습 효과를 확인함으로써 본 발명을 완성하게 되었다.Accordingly, the inventors of the present invention found that pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex promotes elastin synthesis of fibroblasts of skin to improve skin elasticity and pore shrinkage effect, and to achieve superoxide dismutase- It exhibits antioxidative effect and normalizes the level of inflammatory cytokine to normalize skin immunity, anti-inflammation, trouble-improving effect, inhibits skin supernatant proliferation, suppresses acne, has antibacterial effect, promotes synthesis of hyaluronic acid, Thereby completing the present invention.
따라서, 본 발명의 목적은 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 유효성분으로 포함하는 피부 탄력 개선, 모공수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염증, 트러블 개선, 항균, 피부 보습, 피부결 개선용 조성물을 제공하는데 있다.Accordingly, an object of the present invention is to provide a method for improving skin elasticity, pore contraction, antibacterial effect, acne suppression, sebum control, skin barrier improvement, skin immunity normalization, Anti-inflammation, trouble-improving, antibacterial, skin moisturizing, and skin texture improvement.
상기 과제를 해결하기 위한 수단으로서, 본 발명은 식품, 의약 또는 화장료 제조를 위한, 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 유효성분으로 포함하는 피부 탄력 개선, 모공수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염증, 트러블 개선, 항균, 피부 보습 및 피부결 개선용 조성물을 제공한다.As a means for solving the above problems, the present invention relates to a composition for improving skin elasticity, pore contraction, antibacterial activity, antioxidant activity, anti-inflammatory activity, anti- The present invention provides a composition for suppressing acne, controlling sebum, improving skin barrier, normalizing skin immunity, anti-inflammation, improving trouble, antibacterial, skin moisturizing and skin texture improvement.
본 발명에 따른 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물이 피부의 섬유아세포의 엘라스틴 합성을 촉진하여 피부 탄력을 개선시키고, 슈퍼옥시드 디스무타아제 유사 활성을 통해 항산화 효과를 나타내며, 염증성 사이토카인의 수준을 정상화하여 피부 면역 정상화, 항염증, 트러블 개선 효과를 나타내고, 피부 상재균 증식을 억제하여 여드름 억제, 항균 효과가 있으며, 히알루론산의 합성을 촉진하여 피부 보습 효과를 나타냄으로써, 건강기능식품, 의약 또는 화장료 제조에 사용할 수 있다.The pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex according to the present invention promotes elastin synthesis of fibroblasts of the skin to improve skin elasticity, exhibit antioxidative effect through superoxide dismutase-like activity, Normalizing the level of inflammatory cytokine, exhibiting skin immunity normalization, anti-inflammation, trouble-improving effect, suppression of skin supernatant proliferation, suppression of acne, antibacterial effect, promotion of hyaluronic acid synthesis, Health functional food, medicine or cosmetic preparation.
도 1은 본 발명의 대조군 및 실시예에 따른 엘라스틴(Elastin) 생성율을 나타낸 도표이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing the production rate of elastin according to the control group and the example of the present invention. FIG.
이하, 본 발명의 구성을 구체적으로 설명한다.Hereinafter, the configuration of the present invention will be described in detail.
피부 탄력 개선, 모공수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 성분이 실제 피부에 적용 시 우수한 효과를 발휘하기 위해서는 저농도에서 고활성의 피부 탄력 개선, 모공수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 활성을 나타내고, 상기 성분이 포함된 식품을 섭취했을 때 피부로 상기 효능이 나타나거나 피부를 투과하여 흡수되는 능력이 우수하고, 피부 탄력 개선, 모공수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 효과를 나타내기에 충분한 시간 동안 피부에 머무를 수 있도록 휘발성이 낮고, 조성물이나 피부 상에서 활성 성분이 안정하게 유지되고, 건강기능식품, 의약 또는 화장료 등으로의 제조가 용이하며, 또한 체내 및 피부에 안전한 것이 바람직하다. 그러나, 공지의 성분 중 상기 특성을 모두 만족시키는 성분은 흔치 않다. 예를 들어, 몇몇 피부 탄력 개선, 모공수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 활성은 우수하나, 피부에 투과되거나 체내에 흡수되는 능력이 떨어져 실제 피부에 적용하기엔 어렵다. 또 다른 활성 성분들은 친수성이 낮아 건강기능식품이나 의약, 화장품으로 제형화가 어렵다. 또한, 몇몇 피부 탄력 개선, 모공수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 성분들은 열, 광, 또는 산소에 노출되었을 때 상기 활성 성분이 분해되거나 다른 화합물로 변형되어 체내 또는 피부에 적용하기 전에 이미 효과가 사라지는 경우도 있다. In order to exert an excellent effect when applied to actual skin, it is necessary to improve the skin elasticity, pore contraction, antibacterial effect, acne control, sebum control, skin barrier improvement, skin immunity normalization, anti-inflammation, Exhibits activity of improving skin elasticity of active, antibacterial, acne suppression, sebum control, skin barrier improvement, skin immunity normalization, anti-inflammation, trouble improvement, skin moisturizing and skin tone improving activity, It is excellent in the ability of the skin to exhibit the above-mentioned effect or penetrate through the skin and to improve skin elasticity, pore contraction, antibacterial effect, acne suppression, sebum control, skin barrier improvement, skin immunity normalization, anti-inflammation, The composition is low in volatility so as to be able to stay in the skin for a sufficient time to exhibit the improvement effect, Is stable and easily produced in health functional foods, medicines or cosmetics, and is safe in the body and skin. However, the components satisfying all of the above-mentioned characteristics among the known components are not common. For example, some skin elasticity improvement, pore contraction, antibacterial, acne suppression, sebum control, skin barrier improvement, skin immunity normalization, anti-inflammation, trouble improvement, skin moisturizing and skin tone improving activity are excellent, It is difficult to apply to real skin because of its ability to absorb. Other active ingredients have low hydrophilicity and are difficult to formulate into health functional foods, medicines and cosmetics. In addition, when the skin is exposed to heat, light, or oxygen, it is possible to improve the skin elasticity, pore contraction, antibacterial effect, acne suppression, sebum control, skin barrier improvement, skin immunity normalization, The active ingredient may be degraded or transformed into another compound and the effect may already be lost before it is applied to the body or skin.
하기 실시예에서 확인할 수 있는 바와 같이, 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물은 저농도에서 월등히 우수한 섬유아세포의 엘라스틴 합성을 촉진, 슈퍼옥시드 디스무타아제 유사 활성, 염증성 사이토카인 수준을 정상화, 피부 상재균 증식 억제, 히알루론산 합성 촉진 효과를 나타내므로 피부 탄력 개선, 모공수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습, 피부결 개선을 위한 건강기능식품, 의약 또는 화장료 조성물의 유효성분으로 사용할 수 있다.As can be seen in the following examples, pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complexes promote elastin synthesis of fibroblasts, which are superior at low concentrations, superoxide dismutase-like activity, inflammatory cytokine levels It is possible to improve skin elasticity, pore contraction, antibacterial effect, acne control, sebum control, skin barrier improvement, normalization of skin immunity, anti-inflammation, trouble improvement, skin moisturization, Can be used as an active ingredient of a health functional food, a medicine, or a cosmetic composition for improvement.
따라서, 본 발명은 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 유효성분으로 포함하는 피부 탄력 개선, 모공수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습, 피부결 개선용 조성물을 제공한다.Accordingly, the present invention relates to a composition for improving skin elasticity, pore contraction, antibacterial effect, acne suppression, sebum control, skin barrier improvement, skin immunity normalization, anti-inflammation, anti- A composition for improving trouble, skin moisturizing, and skin texture improvement.
본 발명에 있어서, 상기 소나무 껍질 추출물은 식품 원재료 상의 주원료로서, 주성분은 프로안토시아니딘을 비롯한 탄닌과 플라보노이드이고, 고대로부터 사용되어 왔으며, 인체에 무해한 성분이다. In the present invention, the pine bark extract is a main ingredient of a raw material for food, and its main ingredient is tannin and flavonoid including proanthocyanidin, which has been used since ancient times and is harmless to human body.
상기 소나무 껍질 추출물은 당업계에 공지된 방법에 의해 추출될 수 있으며, 그 방법은 특별히 한정되지 않는다. 또는, 시판되고 있는 추출물을 이용할 수 있다.The pine bark extract may be extracted by a method known in the art, and the method is not particularly limited. Alternatively, commercially available extracts can be used.
상기 소나무 껍질 추출물은 예를 들어, 물 및/또는 에탄올 등의 용매에 냉침 또는 가온하여 유효성분을 추출하고 여과한 다음, 여과액을 감압 농축하여 얻을 수 있다.The pine bark extract can be obtained by, for example, cooling or warming with a solvent such as water and / or ethanol, extracting an active ingredient, filtering, and concentrating the filtrate under reduced pressure.
바람직하기로는 상기 소나무 껍질 추출물은 소나무 껍질을 물 및/또는 유기용매로 추출하여 수득한 추출물을 사용할 수 있으며, 상기 유기용매는 극성 유기용매, 비극성 유기용매 또는 이들의 혼합용매일 수 있다. 상기 극성 유기용매는 탄소수 1 내지 5의 저급 알코올, 에틸아세테이트 또는 아세톤일 수 있으며, 비극성 유기용매는 에테르, 클로로포름, 벤젠, 헥산 또는 디클로로메탄일 수 있다. 예를 들어, 상기 탄소수 1 내지 5의 저급 알코올은 메탄올, 에탄올, 프로판올, 부탄올 또는 이소프로판올일 수 있다. Preferably, the pine bark extract may be an extract obtained by extracting pine bark with water and / or an organic solvent. The organic solvent may be a polar organic solvent, a nonpolar organic solvent or a mixture thereof. The polar organic solvent may be a lower alcohol having 1 to 5 carbon atoms, ethyl acetate or acetone, and the nonpolar organic solvent may be ether, chloroform, benzene, hexane or dichloromethane. For example, the lower alcohol having 1 to 5 carbon atoms may be methanol, ethanol, propanol, butanol or isopropanol.
한 구체예에서, 상기 소나무 껍질 추출물은 물 및/또는 에탄올로 추출하여 수득한 추출물일 수 있다.In one embodiment, the pine bark extract may be an extract obtained by extraction with water and / or ethanol.
한 구체예에서 상기 소나무 껍질 추출물은 전술한 추출용매를 이용하여 추출된 1차 추출물을 극성이 다른 추출용매를 이용하여 분획한 분획물을 포함할 수 있다. 예를 들어, 소나무 껍질 추출물은 탄소수 1 내지 5의 알코올로 추출한 후, 에테르, 벤젠, 헥산 등의 극성이 다른 용매로 다시 분획한 분획물 일 수 있다. 상기 분획 시 용매는 2종 이상 사용할 수 있으며, 용매의 극성에 따라 순차적으로 사용하거나 혼합하여 사용하여, 각 용매 추출물을 제조할 수 있다. In one embodiment, the pine bark extract may include a fraction obtained by fractionating the primary extract extracted using the above-described extraction solvent with an extraction solvent having a different polarity. For example, the pine bark extract may be a fraction obtained by extracting with an alcohol having 1 to 5 carbon atoms and then fractionating again with a solvent having a different polarity such as ether, benzene, or hexane. Two or more kinds of solvents may be used for the fractionation, and the solvent extracts may be sequentially used or mixed according to the polarity of the solvent.
본 발명에서, 상기 제조된 추출물 또는 상기 분획과정을 수행하여 수득한 분획물에 대해 여과하거나 농축 또는 건조과정을 수행하여 용매를 제거할 수 있으며, 상기 여과, 농축 및 건조를 모두 수행할 수 있다. 구체적으로 상기 여과는 여과지를 이용하거나 감압여과기를 이용할 수 있고, 농축은 감압 농축기 등을 이용하여 감압 농축할 수 있으며, 건조는 동결건조법을 수행할 수 있다. In the present invention, the extracted extract or the fraction obtained by performing the fractionation process may be filtered, concentrated or dried to remove the solvent, and the filtration, concentration, and drying may all be performed. Specifically, the filtration can be performed using a filter paper or a vacuum filter, and the concentration can be reduced by using a reduced pressure concentrator or the like, and the freeze-drying method can be carried out for drying.
또한, 상기 제조된 추출물 또는 상기 분획과정을 수행하여 수득한 분획물에 대해 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 박층 크로마토그래피(thin layer chromatography) 또는 고성능 액체 크로마토그래피(high performance liquid chromatography) 등의 다양한 크로마토그래피를 이용하여 정제함으로써 추가로 정제된 분획을 얻을 수 있다. The fractions obtained by performing the above-described extract or the fractionation process can be further purified by silica gel column chromatography, thin layer chromatography or high performance liquid chromatography Further purification can be achieved by purification using various chromatographic techniques.
본 발명에 있어서, 상기 소나무 껍질 추출물은 프랑스산 해송 껍질 추출물일 수 있다.In the present invention, the pine bark extract may be a French sea bream peel extract.
본 발명에 있어서, 상기 조성물은 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산을 모두 포함한다.In the present invention, the composition includes pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid.
상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E, 및 감마리놀렌산은 천연 물질로서 오랫동안 사용되어 안정성이 입증되었으므로, 상식할 수 있으면서도 건강 기능 식품의 형태로 제조되어 섭취할 수 있다.Since the pine bark extract, ascorbic acid, vitamin E, and gamma linolenic acid have been used for a long time as a natural substance and proved to be stable, they can be manufactured in the form of health functional foods while being common sense.
본 발명의 피부 탄력 개선, 모공 수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선용 조성물은 식품 제형 제조를 위해 사용할 수 있다. The composition for improving the skin elasticity, pore contraction, antibacterial effect, acne control, sebum control, skin barrier improvement, skin immunity normalization, anti-inflammation, trouble improvement, skin moisturizing and skin texture improvement of the present invention can be used for manufacturing food formulations.
상기 조성물은 소나무 껍질 추출물 1 내지 45 중량%, 아스콜빈산 18 내지 75 중량%, 비타민 E 4 내지 35 중량% 및 감마리놀렌산 2 내지 45 중량%의 비율로 혼합되는 것이 바람직하다. 각 성분의 권장 최소 사용량 이하의 양을 사용할 경우에는 상호간의 상승 효과에 의한 피부 개선 효과를 기대하기 어렵고, 각 성분의 권장 최대 사용량 이상의 양을 사용할 경우에는 사용 함량 증가와 정비례하여 피부 개선 효과가 증가하는 것이 아니며, 또한 원료의 가격이 너무 비싸지기 때문에 상업적으로 적합하지 않다.Preferably, the composition is mixed at a ratio of 1 to 45% by weight of pine bark extract, 18 to 75% by weight of ascorbic acid, 4 to 35% by weight of vitamin E and 2 to 45% by weight of gamma linolenic acid. It is difficult to expect a skin improvement effect due to the mutual synergistic effect when the recommended amount of each ingredient is less than the recommended minimum use amount. When the amount of the ingredient exceeds the recommended maximum use amount, the skin improvement effect is directly increased And is also not commercially suitable because the cost of the raw material is too high.
또한, 본 발명의 한 구체예에서, 상기 조성물은 상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%(바람직하게는 0.0001 중량% 내지 1 중량%)로 포함할 수 있다. 본 발명의 조성물이 상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 0.0001 중량% 미만으로 포함할 경우에는 충분한 피부 탄력 개선, 모공 수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 효과를 기대할 수 없고, 10 중량%를 초과하여 포함할 경우에는 알러지 등 원치 않는 반응이 발생하거나 피부 안전성에 문제가 있을 수 있으므로 이를 방지하기 위한 것이다.In addition, in one embodiment of the present invention, the composition comprises the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex in an amount of 0.0001 wt% to 10 wt% (preferably 0.0001 wt% to 1 wt% Weight%). When the composition of the present invention contains less than 0.0001% by weight of the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex, sufficient skin elasticity improvement, pore shrinkage, antibacterial effect, acne suppression, sebum control, It can not be expected that the skin immunity normalization, anti-inflammation, trouble improvement, skin moisturizing and skin texture improving effect can be expected. If it is contained in an amount exceeding 10% by weight, it can prevent unwanted reactions such as allergies or skin safety problems. .
상기 식품 제형은 상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 음료, 차류, 향신료, 껌, 과자류 등의 식품 소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품을 의미한다. The food formulation is defined as a food prepared by adding the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex to a food material such as beverage, tea, spice, gum and confectionery, or by encapsulation, powdering, do.
상기 식품 제형은 일상적으로 섭취하는 것이 가능하기 때문에 높은 피부 탄력 개선, 모공 수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 효과를 기대할 수 있어 매우 유용하다.Since the food preparation can be taken on a daily basis, the food formulation can be expected to have high skin elasticity, pore contraction, antibacterial effect, acne suppression, sebum control, skin barrier improvement, skin immunity normalization, anti-inflammation, trouble improvement, skin moisturizing and skin texture improvement It is very useful.
상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 식품첨가물로 사용하는 경우, 상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 조성물은 원료에 대하여 15 중량% 이하, 바람직하게는 10 중량% 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.When the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex are used as food additives, the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex may be added intact or used together with other food or food ingredients And can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). In general, the composition of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material, in the production of food or beverage. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range .
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of the food to which the above substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health functional foods in a conventional sense.
본 발명에 있어서, ‘건강기능식품’이라 함은 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 가공된 의학, 의료효과가 높은 식품을 의미한다. 상기 식품은 피부 개선에 유용한 효과를 얻기 위하여 분말, 과립, 정제, 캡슐, 액상, 및 환제를 포함하는 군에서 선택되는 어느 하나의 제형으로 제조될 수 있으나, 당업계에서 통상적으로 사용되는 것이라면 제한없이 사용할 수 있다.In the present invention, the term "health functional food" refers to a food having high medical effect and processed to show a biological control function in addition to nutrition supply. The food may be prepared in any one form selected from the group including powders, granules, tablets, capsules, liquids, and pills in order to obtain a useful effect for skin improvement. Can be used.
식품 제형이 음료인 경우, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 mL 당 일반적으로 약 0.01 ∼ 0.04 g, 바람직하게는 약 0.02 ∼ 0.03 g 이다.When the food is a beverage, various flavors or natural carbohydrates may be added as an additional ingredient such as a normal drink. The above-mentioned natural carbohydrates are sugar alcohols such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
상기 조성물은 식품 조성물에 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예를 들어, 비타민 A, D, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. 또한, 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 데히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시톨류엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 첨가할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용된다.The composition may contain additional ingredients which are commonly used in food compositions and which can improve odor, taste, visual appearance, and the like. For example, vitamins A, D, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid and the like. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn) and copper (Cu) It may also include amino acids such as lysine, tryptophan, cysteine, valine, and the like. In addition, it is also possible to use antiseptics (such as potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate), disinfectants (such as bleaching powder and highly bleached white powder, sodium hypochlorite), antioxidants (butylhydroxyanilide (BHA), butylhydroxytoluene BHT), etc.), coloring agents (such as tar pigments), coloring agents (such as sodium nitrite and sodium acetic acid), bleaching agents (sodium sulfite), seasoning (such as MSG sodium glutamate), sweeteners (such as hypoglycemia, , Food additives such as flavorings (vanillin, lactones, etc.), swelling agents (alum, potassium hydrogen D-tartrate), emulsifiers, emulsifiers, thickeners, encapsulating agents, gum bases, foam inhibitors, ) Can be added. The additives are selected according to the type of food and used in an appropriate amount.
상기 외에 식품 제형은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 식품 제형은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량%당 0.01 ~ 0.1 중량%의 범위에서 선택되는 것이 일반적이다.In addition to the above, the food formulations may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, And the like. Other food formulations may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such an additive is not critical, but is generally selected in the range of 0.01 to 0.1% by weight per 100% by weight of the composition of the present invention.
본 발명의 식품 조성물은 당업계에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조 시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어날 수 있다.The food composition of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients which are conventionally added in the art. Also, unlike general medicine, there is an advantage that there is no side effect that can occur when a medicine is used for a long time by using food as a raw material, and it is excellent in portability.
또한, 본 발명의 피부 탄력 개선, 모공 수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선용 조성물은 의약 제형 제조를 위해 사용할 수 있다.The composition for improving skin elasticity, pore contraction, antibacterial effect, acne control, sebum control, skin barrier improvement, skin immunity normalization, anti-inflammation, trouble improvement, skin moisturizing and skin texture improvement of the present invention can be used for the production of pharmaceutical formulations .
상기 의약 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액의 형태이거나, 엑스제, 분말제, 과립제, 정제 또는 캅셀제의 형태일 수 있다.The pharmaceutical formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules.
또한, 상기 조성물은 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 피부 탄력 개선, 모공 수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 성분을 포함할 수 있을 것이다. 추가적인 피부 탄력 개선, 모공 수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 성분을 포함하게 되면 본 발명의 조성물의 피부 탄력 개선, 모공 수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 효과는 더욱 증진될 수 있을 것이다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. In addition, the composition may further contain one or more active ingredients showing the same or similar functions. For example, it may include known skin elasticity improvement, pore contraction, antibacterial, acne suppression, sebum control, skin barrier improvement, skin immunity normalization, anti-inflammation, trouble-improving, skin moisturizing and skin texture improving ingredients. The composition of the present invention can improve the elasticity of the skin, improve the skin elasticity of the pores, improve the skin elasticity of the composition of the present invention, and improve the skin elasticity, pore contraction, antibacterial effect, acne suppression, sebum control, skin barrier improvement, skin immunity normalization, Shrinkage, antibacterial, acne suppression, sebum control, skin barrier improvement, skin immunity normalization, anti-inflammation, trouble improvement, skin moisturizing and skin texture improvement effect can be further enhanced. When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use.
또한, 본 발명의 조성물은 약학적으로 허용 가능한 담체를 더 포함할 수 있다.In addition, the composition of the present invention may further comprise a pharmaceutically acceptable carrier.
본 발명에서 사용되는 용어, "약학적으로 허용 가능한 담체"란 생물체를 자극하지 않으면서, 주입되는 화합물의 생물학적 활성 및 특성을 저해하지 않는 담체 또는 희석제를 의미할 수 있다. 본 발명에 사용 가능한 상기 담체의 종류는 특별히 제한되지 아니하며 당해 기술 분야에서 통상적으로 사용되고 약학적으로 허용되는 담체라면 어느 것이든 사용할 수 있다. 상기 담체의 비제한적인 예로는, 완충액, 주사용 멸균수, 일반 식염수 또는 인산염 완충 식염수, 슈크로스, 히스티딘, 염 및 폴리솔베이트 등과 같은 여러 성분을 함유할 수 있다. 이들은 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다. 상기 담체는 비자연적 담체 (non-naturally occuring carrier)를 포함할 수 있다.As used herein, the term "pharmaceutically acceptable carrier" may mean a carrier or diluent that does not disturb the biological activity and properties of the compound being injected, without irritating the organism. The type of the carrier that can be used in the present invention is not particularly limited, and any carrier conventionally used in the art and pharmaceutically acceptable may be used. Non-limiting examples of such carriers may contain various components such as buffer, injectable sterile water, normal saline or phosphate buffered saline, sucrose, histidine, salts and polysorbates. These may be used alone or in combination of two or more. The carrier may comprise a non-naturally occuring carrier.
본 발명의 조성물은 경구 또는 비경구로 투여할 수 있으며, 일반 약학 제제의 형태, 예를 들어, 임상 투여 시 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.The composition of the present invention can be administered orally or parenterally, and can be administered in the form of a general pharmaceutical preparation, for example, various forms of oral and parenteral administration at the time of clinical administration. In the case of formulation, a filler, , A binder, a wetting agent, a disintegrant, a surfactant, and the like.
경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 의약 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트(Calcium carbonate), 수크로스(Sucrose) 또는 락토오스(Lactose), 젤라틴 등을 섞어 조제될 수 있다.Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like. These solid preparations can be prepared by mixing the pharmaceutical composition of the present invention with at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin and the like can be prepared.
단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of liquid formulations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used.
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌 글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명에 있어서, '피부 탄력 개선 효과'라 함은 피부에 대한 탄력성이 증가되는 것으로, 피부 탄력의 손실을 억제 또는 저해하거나, 이미 감소된 탄력을 완화시키는 것을 말한다. In the present invention, 'skin elasticity improving effect' refers to an increase in elasticity to the skin, which suppresses or inhibits the loss of skin elasticity, or alleviates the elasticity that has already been reduced.
본 발명에 있어서, '모공 수축 효과'라 함은 확대된 피부의 모공의 크기를 감소시키는 것으로, 노화, 과다한 피지 분비, 각질의 부전각화 등 여러 가지 요인에 의해 모공의 크기가 커질 수 있다.In the present invention, the term 'pore shrinkage effect' refers to a reduction in the size of pores of enlarged skin. The pore size may be enlarged due to various factors such as aging, excess sebum secretion, keratinization, and the like.
본 발명에 있어서, '피부 장벽 개선 효과'라 함은 피부 장벽 기능을 원활하게 하는 것을 말하며, 상기 피부 장벽은 각질세포와 각질세포를 둘러싼 세포간 지질의 라멜라 구조에 의해, 외부에서의 이물질 침입을 막고, 동시에 체내의 수분 및 전해질 등을 체외로 상실하는 것을 막는 것을 의미한다.In the present invention, the 'skin barrier improvement effect' refers to smooth skin barrier function, and the skin barrier can prevent intrusion of foreign substances from outside by the lamellar structure of intercellular lipid surrounding keratinocytes and keratinocytes And prevent the body from losing moisture and electrolytes in the body at the same time.
본 발명에 있어서, '피부 면역 정상화 효과'라 함은 피부 면역이 과잉으로 항진된 상태인 경우에는 면역을 진정화시키고, 한편 피부 면역이 약화되어 있는 경우에는 면역을 항진 또는 부활시켜 정상화시키는 것을 말한다.In the present invention, the term 'skin immunity normalization effect' refers to normalizing immunity when skin immunity is excessive, and normalizing skin immunity when the skin immunity is weakened.
본 발명에 있어서, '항염 효과'라 함은 염증을 억제하는 것을 말하며, 상기 염증은 어떤 자극에 대한 생체조직의 방어반응의 하나로, 조직 변질, 순환 장애와 삼출, 조직 증식의 세가지를 병발하는 복잡한 병변을 말한다. 보다 구체적으로 염증은 선천성 면역의 일부이며 다른 동물에서처럼 인간의 선천성 면역은 병원체에 특이적으로 존재하는 세포 표면의 패턴을 인식한다. 식세포는 그런 표면을 가진 세포를 비자기로 인식하고 병원체를 공격한다. 만일 병원균이 신체의 물리적 장벽을 깨고 들어온다면 염증반응이 일어난다. 염증반응은 상처부위에 침입한 미생물들에 대한 적대 환경을 만드는 비특이적인 방어작용이다. 염증반응에서, 상처가 나거나 외부 감염체가 체내로 들어왔을 때, 초기단계 면역반응을 맡고 있는 백혈구들이 몰려들어 사이토카인을 발현한다. 따라서 세포 내 사이토카인의 발현양이 염증반응 활성화의 지표가 된다. 염증과 관련된 피부질환의 예로는 아토피 피부염, 건선, 방사선, 화학물질, 화상 등에 의해 촉발되는 홍반성 질환, 산 화상, 수포성 피부병, 태선 모양 종류 질환, 알레르기에 기한 가려움증, 지루성 습진, 장미 여드름, 심상성 천포창, 다형 삼출성 홍반, 결절 홍반, 귀두염, 음문염, 원형 탈모증과 같은 염증성 모발 손실, 피부 T-세포 림프종 등이 있으나 이에 제한되는 것은 아니다.In the present invention, the 'anti-inflammatory effect' refers to inhibition of inflammation, and the inflammation is one of defensive reactions of biological tissue against certain stimuli, and is a complex reaction involving tissue degeneration, circulatory disorder and exudation, Lesion. More specifically, inflammation is part of congenital immunity and, like in other animals, human congenital immunity recognizes a pattern of cell surfaces that are specifically present in a pathogen. Phagocytes recognize cells with such surfaces as non-magnetic and attack pathogens. If pathogens break through the physical barriers of the body, an inflammatory reaction occurs. Inflammation is a nonspecific defense that creates hostile environments for microorganisms entering the wound. In the inflammatory response, white blood cells that are responsible for the early stage of immune response, when wounded or infected, enter the body to express cytokines. Therefore, the expression level of intracellular cytokine is an index of inflammatory response activation. Examples of skin diseases associated with inflammation include atopic dermatitis, psoriasis, radiation, chemical substances, inflammatory diseases caused by burns, acid burns, vesicular dermatosis, visceral type diseases, itching due to allergies, seborrheic eczema, rose acne, Inflammatory hair loss such as pemphigus vulgaris, polymorphous exudative erythema, erythema nodosum, erythematosus, pharyngitis, alopecia areata, skin T-cell lymphoma, and the like.
본 발명에 있어서, '트러블 개선 효과'라 함은 알러지, 피부염, 이상각화, 가려움 및 이로 인해 발생되는 염증과 같은 2차 트러블 등을 의미하며, 상기 염증을 억제하여 개선시키는 효과를 의미한다.In the present invention, the 'trouble improving effect' means a secondary trouble such as allergy, dermatitis, abnormal keratinization, itching and inflammation caused thereby, and means an effect of suppressing and improving the inflammation.
본 발명에 있어서, '항균 효과'라 함은 균에 저항하는 능력을 말하며, 세균이나 곰팡이와 같은 미생물의 작용으로부터 방어하기 위해 이루어지는 모든 기작을 의미한다.In the present invention, the term " antibacterial effect " refers to the ability to resist bacteria and means all mechanisms that are performed to defend against the action of microorganisms such as bacteria or fungi.
본 발명에 있어서, '피부 보습 효과'라 함은 피부의 수분이 감소되는 것을 저해 또는 억제하거나 피부의 수분 함유량을 증가시켜 피부 표면을 매끄럽게 하며, 윤기를 부여하는 것을 말한다.In the present invention, the term 'skin moisturizing effect' refers to inhibiting or reducing the decrease of moisture in the skin, or increasing the moisture content of the skin to smooth and smooth the surface of the skin.
본 발명에 있어서, '피부결 개선 효과'라 함은 노화, 스트레스 등의 영향으로 피부 표면이 거칠어지는 것을 억제 또는 저해함으로써 피부 표면을 매끄럽게 하고, 광택을 부여하며, 피부 톤을 밝게 개선하는 것을 말한다.In the present invention, the term " skin texture improving effect " refers to smoothing the skin surface, imparting gloss, and brightening the skin tone by inhibiting or inhibiting roughness of the skin surface due to aging, stress, .
본 발명에 있어서, '여드름 억제' 및 피지 조절 효과'라 함은 피지가 지나치게 많이 분비되면 피부가 번들거리는 것은 물론, 모공이 막혀 여드름이 일어나게 되므로 피지의 분비를 조절하여 여드름을 억제시키는 것을 말한다.In the present invention, the term 'acne suppression' and 'sebum control effect' refers to suppression of acne by regulating the secretion of sebum as the sebaceous glands are clogged as well as the skin is bundled if sebum is secreted too much.
본 발명에 있어서, '유효량'이라 함은 피부 탄력을 개선시키거나, 피부의 장벽을 개선시키거나, 피부의 면역을 정상화시키거나, 염증을 억제하거나, 항균 효과나, 보습 효과나, 피부결을 개선하거나, 피지를 조절할 수 있는 추출물의 양을 의미한다. 본 발명의 조성물이 유효량의 상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 포함할 때 바람직한 피부 탄력 개선, 모공 수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 효과를 제공할 수 있다. 본 발명의 조성물에 포함되는 상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물의 유효량은 조성물이 제품화되는 형태, 상기 화합물이 피부에 적용되는 방법 및 피부에 머무르는 시간 등에 따라 달라질 것이다. 예컨대, 상기 조성물이 약학 제형으로 제품화되는 경우에는 일상적으로 피부에 적용하게 되는 화장품으로 제품화되는 경우에 비해 높은 농도로 상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 포함할 수 있을 것이다. 따라서, 일일 투여량은 상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물의 양을 기준으로 0.1 내지 100 ㎎/㎏이고, 바람직하게는 30 내지 80 ㎎/㎏이고, 더욱 바람직하게는 50 내지 60 mg/kg이며, 하루 1 ∼ 6 회 투여될 수 있다. In the present invention, the term 'effective amount' means an amount effective to improve skin elasticity, to improve skin barrier, to normalize skin immunity, to suppress inflammation, to inhibit antibacterial effect, moisturizing effect, Means the amount of extract that can improve or control sebum. When the composition of the present invention contains an effective amount of the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex, it is desirable to improve skin elasticity, pore contraction, antibacterial effect, acne suppression, sebum control, skin barrier improvement, Anti-inflammation, trouble-improving, skin moisturizing, and skin texture improving effect. The effective amount of the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex contained in the composition of the present invention will vary depending on the form in which the composition is commercialized, the method in which the compound is applied to the skin, and the time on the skin. For example, when the composition is commercialized as a pharmaceutical formulation, it may contain the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex at a higher concentration than when commercialized into cosmetics that are routinely applied to the skin . Therefore, the daily dose is 0.1-100 mg / kg, preferably 30-80 mg / kg, more preferably 50-50 mg / kg, based on the amount of the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex. To 60 mg / kg, and can be administered 1 to 6 times a day.
본 발명의 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.
본 발명의 의약 제형은 피부 외용제 제형을 포함할 수 있다. The pharmaceutical formulations of the present invention may include external preparation for skin.
상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 피부외용제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다. When the pine bark extract, ascorbic acid, vitamin E, and gamma linolenic acid complex are used as an external preparation for skin, it is possible to further include a fatty substance, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, A surfactant, a water, an ionic or nonionic emulsifier, a filler, a sequestering and chelating agent, a preservative, a vitamin, a barrier, a wetting agent, an essential oil, a dye, a pigment, An oily active agent, a lipid vesicle or any other ingredient conventionally used in external preparations for skin, as well as adjuvants conventionally used in the field of skin science. The components can also be introduced in amounts commonly used in the field of dermatology.
상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물이 피부 외용제 제형으로 제공될 경우, 이에 제한되는 것은 아니나, 연고, 패취, 겔, 크림 또는 분무제와 같은 제형을 가질 수 있다.When the pine bark extract, ascorbic acid, vitamin E, and gamma linolenic acid complex are provided as an external preparation for skin, they may have formulations such as, but not limited to, ointments, patches, gels, creams or sprays.
또한, 본 발명의 피부 탄력 개선, 모공 수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선용 조성물은 화장료 제형 제조를 위해 사용될 수 있다.Further, the composition for improving skin elasticity, pore contraction, antibacterial effect, acne control, sebum control, skin barrier improvement, skin immunity normalization, anti-inflammation, trouble improvement, skin moisturization and skin texture improvement of the present invention can be used for manufacturing cosmetic formulations .
상기 화장료 제형은 일반적인 유화 제형 및 가용화 제형의 형태일 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등과 같은 화장수, 훼이셜 로션, 바디로션 등과 같은 유액, 영양 크림, 수분 크림, 아이 크림 등과 같은 크림, 에센스, 화장연고, 스프레이, 젤, 팩, 선 스크린, 메이크업 베이스, 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션, 파우더, 클렌징 크림, 클렌징 로션, 클렌징 오일과 같은 메이크업 제거제, 클렌징 폼, 비누, 바디 워쉬 등과 같은 세정제 등의 제형을 가질 수 있다. The cosmetic formulation may be in the form of a conventional emulsion formulation and a solubilized formulation. For example, creams, essences, cosmetic creams, sprays, gels, packs, sunscreens, make-up bases, liquids such as lotions such as lotion, facial lotion, body lotion, A powder, a cleansing lotion, a makeup removing agent such as a cleansing oil, a cleansing foam, a soap, a body wash, and the like.
또한, 상기 화장품은 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.In addition, the cosmetic product may further comprise, in addition to the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex, a fat substance, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizing agent, a surfactant, a water, an ionic or nonionic emulsifier, a filler, a sequestering and chelating agent, a preservative, a vitamin, a barrier, a wetting agent, an essential oil, a dye, a pigment, a hydrophilic or lipophilic active agent, Lipid vesicles, or any other ingredient conventionally used in cosmetics, as well as adjuvants commonly used in the cosmetics field.
상기 화장료 제형은 유효성분이 단기간 내에 피부에 머무르게 되는 메이크업 제거제, 세정제 등과 같은 워쉬-오프(wash-off) 타입의 화장품의 경우에는 비교적 높은 농도의 상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 포함할 수 있을 것이다. 반면, 유효성분이 장기간 동안 피부에 머무르게 되는 화장수, 유액, 크림, 에센스 등의 리브-온(leave-on) 타입의 화장품의 경우에는 워쉬-오프 타입의 화장품에 비해 낮은 농도의 상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 포함해도 무방할 것이다. 이에 제한되는 것은 아니나, 본 발명의 한 구체예에서, 상기 조성물은 소나무 껍질 추출물 1 내지 45 중량%, 아스콜빈산 18 내지 75 중량%, 비타민 E 4 내지 35 중량% 및 감마리놀렌산 2 내지 45 중량%의 비율로 혼합되어 포함될 수 있다. 본 발명의 조성물에서 각 성분이 권장 최소 사용량 이하의 양을 사용할 경우에는 상호간의 상승 효과에 의한 피부 개선 효과를 기대하기 어렵고, 각 성분의 권장 최대 사용량 이상의 양을 사용할 경우에는 사용 함량 증가와 정비례하여 피부 개선 효과가 증가하는 것이 아니며, 또한 원료의 가격이 너무 비싸지기 때문에 상업적으로 적합하지 않다.In the case of the wash-off type cosmetics such as make-up remover, detergent and the like in which the active ingredient remains on the skin in a short period of time, the cosmetic formulation contains a relatively high concentration of the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid Complex. ≪ / RTI > On the other hand, in the case of leave-on type cosmetics such as lotion, cream, essence and the like in which the active ingredient remains on the skin for a long period of time, the pine bark extract, Columbic acid, vitamin E, and gamma linolenic acid complex. In one embodiment of the present invention, but not limited thereto, the composition comprises 1 to 45% by weight of pine bark extract, 18 to 75% by weight of ascorbic acid, 4 to 35% by weight of vitamin E and 2 to 45% by weight of gamma linolenic acid, As shown in FIG. When the components of the composition of the present invention are used in an amount less than the recommended minimum use amount, it is difficult to expect a skin improvement effect due to mutual synergistic effect. In the case of using an amount exceeding the recommended maximum use amount of each component, The improvement effect of the skin is not increased, and the price of the raw material is too expensive, which is not commercially suitable.
또한, 본 발명의 한 구체예에서, 상기 조성물은 상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%(바람직하게는 0.0001 중량% 내지 1 중량%)로 포함할 수 있다. 본 발명의 조성물이 상기 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산 복합물을 0.0001 중량% 미만으로 포함할 경우에는 충분한 피부 탄력 개선, 모공 수축, 항균, 여드름 억제, 피지 조절, 피부 장벽 개선, 피부 면역 정상화, 항염, 트러블 개선, 피부 보습 및 피부결 개선 효과를 기대할 수 없고, 10 중량%를 초과하여 포함할 경우에는 알러지 등 원치 않는 반응이 발생하거나 피부 안전성에 문제가 있을 수 있으므로 이를 방지하기 위한 것이다.In addition, in one embodiment of the present invention, the composition comprises the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex in an amount of 0.0001 wt% to 10 wt% (preferably 0.0001 wt% to 1 wt% Weight%). When the composition of the present invention contains less than 0.0001% by weight of the pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid complex, sufficient skin elasticity improvement, pore shrinkage, antibacterial effect, acne suppression, sebum control, It can not be expected that the skin immunity normalization, anti-inflammation, trouble improvement, skin moisturizing and skin texture improving effect can be expected. If it is contained in an amount exceeding 10% by weight, it can prevent unwanted reactions such as allergies or skin safety problems. .
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다. Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
실시예Example 1 내지 13: 복합 조성물의 제조 1 to 13: Preparation of composite composition
소나무 껍질 추출물(피크노제놀), 아스콜빈산, 비타민 E 및 감마리놀렌산을 아래의 표 1에 기재된 함량비(단위:%)에 따라 총량이 100mg이 되도록 혼합한 후, 세포 수준에서의 피부 개선효과를 실험하였다. 소나무추출물로는 피크노제놀을 사용하였으며, 감마리놀렌산으로는 달맞이종자유(59% 감마리놀렌산 함유)를 함량 환산하여 사용하였다.Pine bark extract (pycnogenol), ascorbic acid, vitamin E and gamma linolenic acid were mixed to a total amount of 100 mg according to the content ratio (unit:%) shown in the following Table 1, Respectively. Pycnogenol was used as a pine extract, and as the content of gamma linolenic acid, the content of sunflower seed oil (containing 59% gamma linolenic acid) was used.
(피크노제놀)Pine extract
(Pycnogenol)
실험예Experimental Example 1: 복합 조성물의 섬유아세포 엘라스틴( 1: Fibroblast elastin of the composite composition ( ElastinElastin ) 합성 촉진 효과) Synthesis Promotion Effect
엘라스틴 (Elastin)은 콜라겐과 함께 결합조직에 존재하는 단백질로서 고무와 같이 탄력성이 있어 조직의 유연성과 신축성에 관여하고 있다. 피부는 표피와 진피로 구성되어 있고, 진피는 두가지 층으로 나눠진다. 위에 있는 층이 유두층 (Papillary layer)이고, 아래에 있는 층이 망상층 (Reticular layer)이다. 주로 망상층에는 콜라겐이 많은 반면에 유두층에는 엘라스틴 (Elastin)이 풍부하다. 엘라스틴 (Elastin)은 피부에 풍부하게 함유되어 있기 때문에 다른 단백질에 비해 특히 사람의 외모에 많은 영향을 미친다. 피부에 용수철과 같은 장치로 피부의 탄력성과 모공확장 억제에 깊은 관여를 하여 젊음을 유지하는데 있어 매우 중요한 역할을 담당하고 있다 (Aestheric&Spa, 2014(10)).Elastin is a protein that exists in connective tissue together with collagen. It is elastic like rubber, and it is involved in flexibility and stretchability of tissue. The skin consists of epidermis and dermis, and the dermis is divided into two layers. The upper layer is the papillary layer and the lower layer is the reticular layer. There is a lot of collagen mainly in the reticular layer, but there is a lot of elastin in the papilla. Because of its abundance in the skin, Elastin has a lot of impact on human appearance, especially compared to other proteins. (Aestheric & Spa, 2014 (10)), which plays a crucial role in maintaining youthfulness through skin-elasticity and deep involvement in the inhibition of pore enlargement.
복합 조성물의 이러한 엘라스틴(Elastin) 합성 촉진 효과를 확인하기 위해 인간 유래의 정상 섬유아세포를 2×105개를 6-well-plate에서 24시간 동안 배양하고, 아무 것도 처리하지 않은 대조군 및 실시예의 복합물 시료 50μg/mL 를 처리한 실험군을 준비하였다. 다시 48시간 동안 배양한 후, 섬유아세포에서 새롭게 합성된 엘라스틴 양은 상업적으로 이용가능한 Human elastin ELISA kit(MyBioSource, Inc., USA)를 이용하여 측정하여 그 양을 단백질 양으로 보정하였다. 실험 결과는 아무 것도 처리하지 않은 대조군을 100%로 하여 그 결과를 도 1에 나타내었다.In order to confirm the promoting effect of the elastin synthesis of the composite composition, 2 × 10 5 human-derived normal fibroblasts were cultured in a 6-well plate for 24 hours, and the mixture of the control group and the example An experimental group treated with 50 μg / mL of sample was prepared. After 48 hours of incubation, the amount of newly synthesized elastin in fibroblasts was measured using a commercially available Human elastin ELISA kit (MyBioSource, Inc., USA), and the amount of elastin was corrected to the amount of protein. Experimental results are shown in Fig. 1, in which the control group in which nothing is treated is regarded as 100%.
도 1에서 보는 바와 같이, 소나무 추출물(피크노제놀), 아스콜빈산, 비타민 E 및 감마리놀렌산을 단독 혹은 2종 내지 3종을 혼합하여 사용한 경우보다 4종을 모두 사용하였을 때의 엘라스틴 생성율이 크게 증가하는 것을 알 수 있었다. 이는 각 성분의 상호 간의 상승 효과에 의한 것임을 확인할 수 있다.As shown in FIG. 1, the production rate of elastin significantly increased when four kinds of pine extract (pycnogenol), ascorbic acid, vitamin E and gamma linolenic acid were used alone or in combination of two or three kinds thereof . This can be confirmed by the synergistic effect of each component.
실험예Experimental Example 2: 복합 조성물의 2: 슈퍼옥시드Superoxide 디스무타아제Dismutase 유사 활성 확인 Identify similar activity
활성산소 (Free-Radicals)은 다른 분자와의 상호 작용으로 한 국을 잃어버린 산소분자를 말한다. 이 분자들은 매우 불안정한 상태로, 세포 조직에 손상을 입히게 된다. 활성산소는 노화, 특히 피부 노화의 원인물질로 작용하고 있다. 활성산소는 정상적인 대사과정에서도 생성이 되지만, 피부 노화에 영향을 주는 활성산소는 주로 피부에 대한 자외선의 작용으로 생성된다. 이들은 항산화 효소와 비효소적 항산화제들로 구성된 피부 항산화 방어망을 파괴함으로써, 지질의 과산화 및 단백질의 산화를 촉진하는 단백질 분해효소의 활성화, 콜라겐 및 엘라스틴 (Elastin)의 사슬절단, 피부면역기능을 억제시켜 그 결과 탄력감소, 모공확장, 주름살 및 기미, 주근깨 등 피부의 노화가 가속화 된다. 따라서 피부 세포를 보호하고 피부노화를 지연, 예방하기 위해서는 활성산소의 과잉 생성을 억제하고, 활성화된 활성산소를 제거해야 한다 (홍재기, 대한피부미용학회지, 2009; 7(2): 51-62).Free-Radicals refers to oxygen molecules that have lost one state due to their interaction with other molecules. These molecules are very unstable and damage cell tissue. Active oxygen acts as a causative agent of aging, especially skin aging. Active oxygen is also produced during normal metabolism, but active oxygen, which affects skin aging, is produced mainly by the action of ultraviolet rays on the skin. They break down skin antioxidant defenses consisting of antioxidant enzymes and non-enzymatic antioxidants, inhibit lipid peroxidation, activation of proteolytic enzymes that promote protein oxidation, chain cleavage of collagen and elastin, and skin immune function As a result, elasticity reduction, pore enlargement, wrinkles and spots, freckles and skin aging is accelerated. Therefore, in order to protect the skin cells and delay or prevent aging of the skin, it is necessary to inhibit the excessive production of active oxygen and to remove the active oxygen (Hong Ji Kee, 2009; 7 (2): 51-62) .
복합 조성물의 이러한 슈퍼옥시드 디스무타아제(Superoxide dismutase, SOD) 유사 활성은 Marklund & Marklund (1974)의 방법에 따라 과산화수소(H2O2)로 전환시키는 반응을 촉매하는 피롤갈롤(pyrogallol)의 생성량을 측정하여 SOD 유사 활성으로 나타내었다. 즉, 50μg/mL의 시료 용액에 Tris-HCL 완충용액 (50mM tris + 10mM EDTA, pH 8.5) 260 μl와 7.2mM 피로갈롤 20μl를 가하여 25℃에서 10분간 반응시킨 후, 5N HCl 10μl를 첨가하여 반응을 정시시키고 반응액 중 산화된 피로갈롤의 양을 420nm의 흡광도에서 측정하였다. 실험 결과는 시료 처리군과 대조군의 흡광도 차이를 백분율로 나타내어, 그 결과를 하기 표 2에 나타내었다.This superoxide dismutase (SOD) -like activity of the composite composition is determined by the amount of pyrogallol that catalyzes the conversion of hydrogen peroxide (H 2 O 2 ) according to the method of Marklund & Marklund (1974) Were measured and expressed as SOD-like activity. That is, 260 μl of Tris-HCl buffer (50 mM tris + 10 mM EDTA, pH 8.5) and 20 μl of 7.2 mM pyrogallol were added to a sample solution of 50 μg / mL and reacted at 25 ° C. for 10 minutes. Then, 10 μl of 5N HCl was added And the amount of oxidized pyrogallol in the reaction solution was measured at an absorbance of 420 nm. The experimental results show the difference in absorbance between the sample-treated group and the control group as a percentage, and the results are shown in Table 2 below.
상기 실험 결과는 하기 표 2에 나타내었다. 하기 표 2에서 p63 증가 배수의 수치는 대조군(BPE 첨가한 CNT-57 배지) 대비 배수를 의미한다.The experimental results are shown in Table 2 below. In Table 2 below, the numerical value of the increase in p63 is a multiple of the control group (CNT-57 medium supplemented with BPE).
표 2에 나타난 바와 같이, 소나무추출물(피크노제놀), 아스콜빈산, 비타민 E 및 감마놀렌산을 2종 내지 3종을 혼합하여 사용한 경우보다 4종을 모두 사용하였을 때 강력한 항산화제인 아스콜빈산(실시예 2)과 유사하게 SOD 유사 활성이 나타났음을 알 수 있었다. 이는 각 성분의 상호 간의 상승 효과에 의한 것임을 확인할 수 있다.As shown in Table 2, when four kinds of pine tree extract (pycnogenol), ascorbic acid, vitamin E and gamma-phenolic acid were used in combination of two or three kinds, ascorbic acid (a powerful antioxidant) Similar to Example 2, SOD-like activity was observed. This can be confirmed by the synergistic effect of each component.
실험예Experimental Example 3: 복합 조성물의 염증성 사이토카인 수준의 정상화 효과 3: Normalization of Inflammatory Cytokine Levels of Composite Compositions
면역계는 생물체 내에서 병원체와 종양 세포 등을 탐지한 다음 죽임으로써 질병으로부터 생명체를 보호하는 기능을 지닌 생물학적인 구조 및 과정을 의미한다. 인체 내에서 이러한 면역기능이 제대로 작동하지 않을 경우 알레르기 (allergy), 자가면역질환, 면역결핍증 등 신체의 기능을 떨어뜨리는 다양한 면역질환이 발생하게 된다.The immune system refers to biological structures and processes that have the function of protecting living organisms from diseases by detecting pathogens, tumor cells, and the like in living organisms and then killing them. If the immune system does not function properly in the human body, various immune diseases such as allergy, autoimmune disease, immune deficiency and the like may be caused.
최근 대기 중 황사와 미세먼지 등의 오염물질이 점차 많아지면서, 특히, 외부환경에 노출되는 피부의 면역 불균형 문제가 심각해지고 있다. 이중 면역과민반응인 알레르기 증상을 보이는 환자들이 늘어나고 있다. 피부 알레르기 종류에는 다양한 증상들이 있는데, 그 중에서도 아토피피부염과 건선이 대표적인 피부 알레르기 질환으로 꼽힌다Recently, as pollutants such as dust and fine dust are gradually increasing in the atmosphere, the immune unbalance problem of the skin exposed to the external environment becomes serious. The number of patients who are allergic to double immunosuppression is increasing. There are various symptoms of skin allergy, among which atopic dermatitis and psoriasis are the most common skin allergic diseases
아토피 피부염은 면역학적으로 주로 제2형 보조T세포에 의해 매개되고, 흔히 알레르겐 특이 IgE 수치와 총 IgE 수치의 상승을 동반한다. 반면에 건선은 주로 제1형 보조 T세포에 의해 매개되고, 높은 수치의 interferon-γ가 동반되며, 제17형 보조 T cell에 의한 높은 수치의 interleukin-17A, interleukin-17F, and interleukin-22의 분비를 동반한다(오영준, 대한피부과학회지, 2014; 52(3): 207-208). Atopic dermatitis is immunologically mediated mainly by type 2 Auxiliary T cells and is commonly accompanied by elevated levels of allergen specific IgE and total IgE. On the other hand, psoriasis is mainly mediated by type I Auxiliary T cells, accompanied by high levels of interferon-γ, and high levels of interleukin-17A, interleukin-17F, and interleukin-22 (O, Young, Joon, Korean Journal of Dermatology, 2014; 52 (3): 207-208).
복합 조성물의 이러한 염증성 사이토카인 억제 수준을 평가하기 위해, 마우스(mouse) 대식세포 RAW 264.7 세포를 1×105개/ml의 농도로 96-well-plate에서 24시간 동안 배양한 후, LPS (1μg/ml) 처리하였다. 한시간 후 실시예의 복합 조성물을 10μg/mL농도로 처리하고, 24시간 배양 후에 생성된 IgE와 INF-γ의 양은 상층액을 취하여 상업적으로 이용가능한 IgE Mouse ELISA Kit (abcam, Inc. UK), Interferon gamma (IFNG) Mouse ELISA Kit (abcam, Inc., UK)를 이용하여 측정하였다. 실험 결과는 LPS (1μg/ml)만 처리하고 시료는 처리하지 않은 대조군을 100%로 하여 각각의 결과를 하기 표 3에 나타내었다.To evaluate this level of inflammatory cytokine inhibition of the composite composition, mouse macrophage RAW 264.7 cells were cultured in a 96-well plate at a concentration of 1 x 10 5 cells / ml for 24 hours, and LPS (1 μg / ml). The amount of IgE and INF-γ produced after culturing for 24 hours was measured by using a commercially available IgE Mouse ELISA Kit (abcam, Inc. UK), Interferon gamma (IFNG) Mouse ELISA Kit (abcam, Inc., UK). Experimental results were shown in Table 3 below, except that LPS (1 μg / ml) was treated only and the control group without treatment was 100%.
표 3에 나타난 바와 같이, 소나무추출물(피크노제놀), 아스콜빈산, 비타민 E 및 감마리놀렌산을 단독 혹은 2종 내지 3종을 혼합하여 사용한 경우보다 4종을 모두 사용하였을 때 염증성 사이토카인이 정상 수준으로 억제되는 것을 알 수 있었다. 이는 각 성분의 상호 간의 상승 효과에 의한 것임을 확인할 수 있다.As shown in Table 3, when four kinds of pine extract (pycnogenol), ascorbic acid, vitamin E and gamma linolenic acid were used singly or in combination of two or three kinds, the inflammatory cytokine level was normal . This can be confirmed by the synergistic effect of each component.
실험예Experimental Example 4: 복합 조성물의 피부 4: Skin of the composite composition 상재균Supernatant 증식 억제 효과 확인 Confirming the proliferation inhibitory effect
피부에는 다양하고 매우 많은 미생물들이 서식하고 있으며, 유익균과 유해균이 균형을 이루고 있다. 하지만 그 균형이 깨지면 유해 피부 상재균에 의해서 다양한 피부질환이 발생되게 된다. 유해 피부 상재균은 여드름균, 비듬균, 포도상구균 등이 대표적이다. 여드름균은 일반적으로 호르몬과 외부적 영향에 의해 피지가 모낭관 밖으로 배출되지 못하여 피부 모공이 막힌 경우 증식하여 여드름의 원인이 된다. 포도상구균은 전세계적으로 발견되는 피부상재균이며, 사람이나 동물의 표피에 다양한 질병을 야기 시킨다 (박수남, 한국미생물학회지, 2010; 38(1): 112-115).There are many different microorganisms in the skin, and beneficial bacteria and harmful bacteria are balanced. However, when the balance is broken, various skin diseases are caused by the harmful skin scab. The harmful skin supernatant is typical of acne bacteria, stomach bacteria, staphylococcus. Acne bacterium is generally caused by hormones and external influences, sebum can not be discharged out of the hair follicle, and when the skin pores are clogged, they multiply and cause acne. Staphylococcus aureus is a skin-damaging bacterium found all over the world and causes various diseases in the epidermis of humans and animals (Park, Soo-nam, Korea Microbiology Journal, 2010; 38 (1): 112-115).
피부 상재균 증식 억제 효과는 액체 배지 희석법에 의해 여드름 균과 포도상구균에 대한 최소억제농도(Minimum Inhibitory Concentration, MIC)를 통해 측정하였다. 여드름 균은 35℃에서 48시간 동안 혐기 조건으로 배양한 후 시험에 사용하였으며, 포도상 구균은 37℃에서 18시간 동안 배양한 후 사용하였다. 각각의 균은 2×106 CFU/well이 되도록 조절하여 시료와 함께 18시간 동안 배양한 후, 육안 및 현미경으로 균의 성장을 관찰하였고, 흡수파장 540nm에서 흡광도를 측정하여, 순수배양액과 흡광도 값과 같은 결과를 얻은 것을 최소억제농도로 결정하였다. 여드름 균과 포도상구균의 최소억제농도는 하기 표 4에 나타내었다.The inhibition effect on skin flora was measured by liquid medium dilution method using Minimum Inhibitory Concentration (MIC) for acne and Staphylococcus aureus. Acne bacteria were cultured at 35 ℃ for 48 hours under anaerobic conditions. Staphylococci were cultured at 37 ℃ for 18 hours. Each of the bacteria was adjusted to 2 × 10 6 CFU / well and incubated with the sample for 18 hours. The bacterial growth was observed with the naked eye and a microscope, and the absorbance was measured at an absorption wavelength of 540 nm. Was determined as the minimum inhibitory concentration. The minimum inhibitory concentrations of acne and staphylococci are shown in Table 4 below.
(Propionibacterium acnes)Acne bacteria
( Propionibacterium acnes )
(Staphylococcus aureus)Staphylococcus
( Staphylococcus aureus )
표 4에 나타난 바와 같이, 소나무추출물(피크노제놀), 아스콜빈산, 비타민 E 및 감마리놀렌산을 단독 혹은 2종 내지 3종을 혼합하여 사용한 경우보다 4종을 모두 사용하였을 때 유해 피부 증식균 생장이 억제되는 것을 알 수 있었다. 이는 각 성분의 상호 간의 상승 효과에 의한 것임을 확인할 수 있다.As shown in Table 4, when four kinds of pine extract (pycnogenol), ascorbic acid, vitamin E and gamma linolenic acid were used alone or in combination of two or three kinds, the growth of harmful skin growth bacteria was inhibited . This can be confirmed by the synergistic effect of each component.
실험예Experimental Example 5: 복합 조성물의 히알루론산 합성 촉진 효과 5: Promotion of hyaluronic acid synthesis promotion of the composite composition
피부 노화가 진행됨에 따라 피부의 구조를 지탱하는 기본 버팀목 역할을 하는 섬유조직으로 된 콜라겐과 엘라스틴 (Elastin)이 경화되고, 불용성이 된다. 세포 사이와 콜라겐, 엘라스틴 (Elastin) 등의 섬유질 사이를 채우고 있는 물질들을 기질이라고 하며, 수분을 보유하는 능력이 매우 강력한데, 이러한 기질 중 대표적인 것이 히알루론산(Hyaluronic acid)과 무코다당류(Mucopolysaccharides)들 이다. 히알루론산 (Hyaluronic acid)은 관절액과 피부 등 세포내 조직에 넓게 분포되어 있는 다당류이다. N-아세틸글루코사민과 글루코론산이 결합한 히알루로난의 폴리머로 보습성과 점성을 가지고 있다. 노화가 진행됨에 따라 이러한 물질이 감소하면 피부 건조증이 유발되고, 피부의 탄력이 약해지게 된다(김윤범, 동의생리병리학회지, 2010; 24(4): 533-542).As the aging of the skin progresses, collagen and elastin, which are the fibrous tissues that serve as the basic backing for supporting the structure of the skin, are hardened and become insoluble. Cells, collagen, and elastin are called substrates, and their ability to retain moisture is very strong. Typical of these substrates are hyaluronic acid and mucopolysaccharides to be. Hyaluronic acid (Hyaluronic acid) is a polysaccharide widely distributed in intracellular tissues such as joint fluid and skin. It is a polymer of hyaluronan, which is a combination of N-acetylglucosamine and glucuronic acid, and has moisturizing and viscosity. As aging progresses, a decrease in these substances causes dry skin and weakens the elasticity of the skin (Kim, Yoon Bum, Journal of Physiology and Pathology, 2010; 24 (4): 533-542).
복합 조성물의 히알루론산(Hyaluronic acid) 합성 효과를 확인하기 위해 인간 유래의 정상 섬유아세포를 상기 실험예 1과 동일하게 배양한 후 시료를 처리하였다. 배양액으로부터 새로 생성된 히알루론산은 상업적으로 이용가능한 Human Hyaluronic Acid ELISA Kit(MyBioSource, Inc., USA)를 이용하여 측정하고, 그 양을 단백질 양으로 보정하였다. 실험 결과는 아무 것도 처리하지 않은 대조군을 100%로 하였고, 그 결과를 하기 표 5에 나타내었다.In order to confirm the effect of hyaluronic acid synthesis of the composite composition, human-derived normal fibroblasts were cultured in the same manner as in Experimental Example 1, and treated with samples. The newly generated hyaluronic acid from the culture was measured using a commercially available Human Hyaluronic Acid ELISA Kit (MyBioSource, Inc., USA), and the amount was corrected to the amount of protein. The experimental results are shown in Table 5 below.
표 5에 나타난 바와 같이, 소나무추출물(피크노제놀), 아스콜빈산, 비타민 E 및 감마리놀렌산을 단독 혹은 2종 내지 3종을 혼합하여 사용한 경우보다 4종을 모두 사용하였을 때 히알루론산 생성율이 크게 증가하는 것을 알 수 있었다. 이는 각 성분의 상호 간의 상승 효과에 의한 것임을 확인할 수 있다.As shown in Table 5, hyaluronic acid production rate was significantly increased when all four kinds of pine extract (pycnogenol), ascorbic acid, vitamin E and gamma linolenic acid were used alone or in combination of two or three kinds . This can be confirmed by the synergistic effect of each component.
이하, 본 발명의 복합물을 함유하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, formulation examples of the composition containing the complex of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described.
[[ 제제예Formulation example 1] 식품의 제조 1] Manufacturing of food
1. 건강 식품의 제조1. Manufacture of health food
소나무 껍질 추출물 20㎎Pine bark extract 20 mg
아스콜빈산 300mgAscorbic acid 300 mg
비타민 E 100mgVitamin E 100mg
감마리놀렌산 300mgGamma linolenic acid 300 mg
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 ㎍70 [mu] g of vitamin A acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎0.13 mg vitamin B1
비타민 B2 0.15 ㎎0.15 mg of vitamin B2
비타민 B6 0.5 ㎎0.5 mg vitamin B6
비타민 B12 0.2 ㎍0.2 [mu] g vitamin B12
비타민 C 10 ㎎10 mg vitamin C
비오틴 10 ㎍Biotin 10 μg
니코틴산아미드 1.7 ㎎Nicotinic acid amide 1.7 mg
엽산 50 ㎍50 ㎍ of folic acid
판토텐산 칼슘 0.5 ㎎Calcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 ㎎1.75 mg of ferrous sulfate
산화아연 0.82 ㎎0.82 mg of zinc oxide
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎15 mg of potassium phosphate monobasic
제2인산칼슘 55 ㎎Secondary calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium citrate 90 mg
탄산칼슘 100 ㎎100 mg of calcium carbonate
염화마그네슘 24.8 ㎎24.8 mg of magnesium chloride
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
2. 건강 음료의 제조2. Manufacture of health drinks
소나무 껍질 추출물 20㎎Pine bark extract 20 mg
아스콜빈산 300mgAscorbic acid 300 mg
비타민 E 100mgVitamin E 100mg
감마리놀렌산 300mgGamma linolenic acid 300 mg
구연산 1000 ㎎Citric acid 1000 mg
올리고당 100 g100 g of oligosaccharide
매실농축액 2 gPlum concentrate 2 g
타우린 1 gTaurine 1 g
정제수를 가하여 전체 900 ㎖Purified water was added to a total of 900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
[[ 제제예Formulation example 2] 의약 제제의 제조 2] Manufacture of pharmaceutical preparations
1. 캡슐의 제조1. Preparation of capsules
소나무 껍질 추출물 20㎎Pine bark extract 20 mg
아스콜빈산 300mgAscorbic acid 300 mg
비타민 E 100mgVitamin E 100mg
감마리놀렌산 300mgGamma linolenic acid 300 mg
레시틴 15㎎Lecithin 15 mg
대두유 165㎎Soybean oil 165 mg
캡슐기제 300mgCapsule base 300 mg
상기의 성분을 혼합한 후, 통상의 캡슐의 제조방법에 따라서 제조하였다.After mixing the above components, they were prepared according to the usual capsule manufacturing method.
[제제예 3] 화장품의 제조 [ Formulation Example 3] Production of cosmetics
1. 영양크림의 제조1. Manufacture of nutritional cream
하기 조성과 같이, 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산을 함유하는 복합물을 유효성분으로 포함하는 영양크림을 통상의 방법에 따라 제조하였다.A nutritional cream containing, as an active ingredient, a complex containing pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid as the following composition was prepared according to a conventional method.
소나무 껍질 추출물 0.2 중량%0.2% by weight of pine bark extract
아스콜빈산 1 중량%1% by weight ascorbic acid
비타민 E 1 중량%1% by weight of vitamin E
감마리놀렌산 1 중량%1% by weight of gamma linolenic acid
베타-1,3-글루칸 5.0 중량%Beta-1,3-glucan 5.0 wt%
밀납 10.0 중량%Wax 10.0 wt%
폴리솔베이트60 1.5 중량%
피이지 60 경화피마자유 2.0 중량%≪ tb > < tb > < tb >
솔비탄세스퀴올레이트 0.5 중량%0.5% by weight of sorbitan sesquioleate
유동파라핀 10.0 중량%Liquid paraffin 10.0 wt%
스쿠알란 5.0 중량%Squalane 5.0 wt%
카프릴릭/카프릭트리글리세라이드 5.0 중량%Caprylic / capric triglyceride 5.0 wt%
글리세린 5.0 중량%Glycerin 5.0 wt%
부틸렌글리콜 3.0 중량%3.0% by weight of butylene glycol
프로필렌글리콜 3.0 중량%3.0% by weight of propylene glycol
트리에탄올아민 0.2 중량%0.2% by weight triethanolamine
방부제 0.05 중량%Preservative 0.05 wt%
색소 0.05 중량%0.05% by weight of pigment
향료 0.05 중량%0.05% by weight fragrance
정제수 to 100 중량%Purified water to 100%
[[ 제제예Formulation example 4] 피부 외용제의 제조 4] Production of external preparation for skin
1. 연고의 제조1. Manufacture of ointment
하기 조성과 같이, 소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산을 함유하는 복합물을 유효성분으로 포함하는 연고를 통상의 방법에 따라 제조하였다.An ointment containing, as an active ingredient, a composite containing pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid, as the following composition, was prepared according to a conventional method.
소나무 껍질 추출물 0.2 중량%0.2% by weight of pine bark extract
아스콜빈산 1 중량%1% by weight ascorbic acid
비타민 E 1 중량%1% by weight of vitamin E
감마리놀렌산 1 중량%1% by weight of gamma linolenic acid
베타-1,3-글루칸 10.0 중량%Beta-1,3-glucan 10.0 wt%
밀납 10.0 중량%Wax 10.0 wt%
폴리솔베이트60 5.0 중량%
피이지 60 경화피마자유 2.0 중량%≪ tb > < tb > < tb >
솔비탄세스퀴올레이트 0.5 중량%0.5% by weight of sorbitan sesquioleate
바셀린 5.0 중량%Vaseline 5.0 wt%
유동파라핀 10.0 중량%Liquid paraffin 10.0 wt%
스쿠알란 5.0 중량%Squalane 5.0 wt%
쉐어버터 3.0 중량%SHARE BUTTER 3.0 wt%
카프릴릭/카프릭트리글리세라이드 5.0 중량%Caprylic / capric triglyceride 5.0 wt%
글리세린 10.0 중량%Glycerin 10.0 wt%
프로필렌글리콜 10.2 중량%Propylene glycol 10.2 wt%
트리에탄올아민 0.2 중량%0.2% by weight triethanolamine
방부제 0.05 중량%Preservative 0.05 wt%
색소 0.05 중량%0.05% by weight of pigment
향료 0.05 중량%0.05% by weight fragrance
정제수 to 100 중량%Purified water to 100%
Claims (15)
A composition containing pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid as an active ingredient.
소나무 껍질 추출물은 소나무 껍질을 물, 에탄올 및 이들의 혼합물로 이루어진 군으로부터 선택된 어느 하나의 용매로부터 추출하여 얻은 추출물인 피부 탄력 개선용 조성물.
The method according to claim 1,
Wherein the pine bark extract is an extract obtained by extracting pine bark from any one solvent selected from the group consisting of water, ethanol and a mixture thereof.
조성물은 피부 탄력 개선용 건강기능식품, 의약 또는 화장료 제조를 위한 것인, 피부 탄력 개선용 조성물.
The method according to claim 1,
Wherein the composition is for the production of a health functional food, a medicine or a cosmetic composition for improving skin elasticity.
조성물은 소나무 껍질 추출물 1 내지 45 중량%, 아스콜빈산 18 내지 75 중량%, 비타민 E 4 내지 35 중량% 및 감마리놀렌산 2 내지 45 중량%의 비율로 혼합된 것인, 피부 탄력 개선용 조성물.
The method according to claim 1,
Wherein the composition is mixed at a ratio of 1 to 45% by weight of pine bark extract, 18 to 75% by weight of ascorbic acid, 4 to 35% by weight of vitamin E and 2 to 45% by weight of gamma linolenic acid.
전체 조성물 100 중량%에 대하여,
소나무 껍질 추출물, 아스콜빈산, 비타민 E 및 감마리놀렌산을 함유하는 복합물의 함량은 0.001 내지 100 중량%인, 피부 탄력 개선용 조성물.
The method according to claim 1,
On the basis of 100% by weight of the total composition,
Wherein the content of the composite containing pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid is 0.001 to 100% by weight.
A composition containing pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid as active ingredients.
조성물은 모공 수축, 항균, 여드름 억제 및 피지 조절용 건강기능식품, 의약 또는 화장료 제조를 위한 것인, 모공 수축, 항균, 여드름 억제 및 피지 조절용 조성물.
The method according to claim 6,
Wherein the composition is for the production of a health functional food, a medicine or a cosmetic for pore contraction, antibacterial, acne inhibition and sebum control, a composition for shrinking pores, antibacterial, acne inhibiting and sebum control.
A composition containing pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid as an active ingredient.
조성물은 피부 장벽 개선용 건강기능식품, 의약 또는 화장료 제조를 위한 것인, 피부 장벽 개선용 조성물.
9. The method of claim 8,
Wherein the composition is for the manufacture of a health functional food, a medicament or a cosmetic for improving skin barrier.
A composition for improving normalization of skin immunity, anti-inflammation, and trouble, comprising a complex containing pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid as an active ingredient.
조성물은 피부 면역 정상화, 항염, 트러블 개선용 건강기능식품, 의약 또는 화장료 제조를 위한 것인, 피부 면역 정상화, 항염, 트러블 개선용 조성물.
11. The method of claim 10,
A composition for skin immunization normalization, anti-inflammation, and trouble-improving, wherein the composition is for the preparation of a health functional food, a medicine or a cosmetic preparation for skin immunization normalization, anti-inflammation, trouble improvement.
A composition containing pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid as an active ingredient.
조성물은 피부 보습용 건강기능식품, 의약 또는 화장료 제조를 위한 것인, 피부 보습용 조성물.
13. The method of claim 12,
Wherein the composition is for the production of a health functional food, a medicine or a cosmetic for skin moisturizing.
A composition containing pine bark extract, ascorbic acid, vitamin E and gamma linolenic acid as an active ingredient.
조성물은 피부결 개선용 건강기능식품, 의약 또는 화장료 제조를 위한 것인, 피부결 개선용 조성물.
15. The method of claim 14,
Wherein the composition is for the manufacture of a health functional food, a medicament or a cosmetic composition for improving skin texture.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150144664 | 2015-10-16 | ||
KR1020150144664 | 2015-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20170045085A true KR20170045085A (en) | 2017-04-26 |
Family
ID=58705082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150180221A KR20170045085A (en) | 2015-10-16 | 2015-12-16 | Composition for improving skin and its use |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20170045085A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102160358B1 (en) * | 2019-04-15 | 2020-09-28 | 인천대학교 산학협력단 | Electrochemical sensor detecting dopamine using nitrogen-doped carbon sphere having au-ag alloy nanodots and platinum and method of the same |
KR102695072B1 (en) * | 2024-02-05 | 2024-08-14 | 빅벨 주식회사 | A skin or hair cleansing and moisting composition, and a multifunctional all-in-one cosmetic comprising the same |
-
2015
- 2015-12-16 KR KR1020150180221A patent/KR20170045085A/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102160358B1 (en) * | 2019-04-15 | 2020-09-28 | 인천대학교 산학협력단 | Electrochemical sensor detecting dopamine using nitrogen-doped carbon sphere having au-ag alloy nanodots and platinum and method of the same |
KR102695072B1 (en) * | 2024-02-05 | 2024-08-14 | 빅벨 주식회사 | A skin or hair cleansing and moisting composition, and a multifunctional all-in-one cosmetic comprising the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20170025375A (en) | Composition for improving skin | |
KR20150087145A (en) | Composition for improving skin | |
KR102472974B1 (en) | Composition for improving skin | |
KR20170045085A (en) | Composition for improving skin and its use | |
KR102689774B1 (en) | Composition for improving skin | |
KR20170025355A (en) | Composition for improving skin | |
KR20150087146A (en) | Composition for improving skin | |
KR101989479B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR20180060611A (en) | Composition for improving skin | |
KR101720712B1 (en) | Composition for improving skin comprising levistilide A | |
KR102183896B1 (en) | Composition for improving skin | |
KR20150088973A (en) | Composition for improving skin | |
KR20170025363A (en) | Composition for improving skin | |
KR20170025353A (en) | Composition for improving skin | |
KR101672841B1 (en) | Composition for improving skin | |
KR102397926B1 (en) | Composition for improving skin | |
KR20180060607A (en) | Composition for improving skin | |
KR102000516B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR20190033871A (en) | Complex cosmetic composition for improving skin-aging | |
KR20180060610A (en) | Composition for improving skin | |
KR20180072381A (en) | Composition for improving skin condition comprising extract of Pisum sativum var. arvense (L.) Poir. | |
KR20170025364A (en) | Composition for improving skin | |
KR20170025359A (en) | Composition for improving skin | |
KR20170025371A (en) | Composition for improving skin | |
KR20170025373A (en) | Composition for improving skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |